SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

From near-death in Gaza to a $100 million exit: Itamar Ben Hemo’s extraordinary journey

Mixpanel is here to help gaming companies democratize their data

Here’s how gaming brands can reach wider audiences: “Never make assumptions!”

Israel’s gaming sector is 2% of its GDP - so why is the government ignoring it?

Buzz

Most popular

Daily

Weekly

1

From near-death in Gaza to a $100 million exit: Itamar Ben Hemo’s extraordinary journey

2

Defense tech is booming—but who will actually win?

3

Windward acquired for $270M by FTV Capital, doubling its IPO valuation

4

$41B in exits: Why Israeli cyber startups are a global powerhouse

5

TechAir flights from Israel to New York take off January 21

Patent

20 stories about Patent

IP protection might just save the tech companies from their crisis

29.08.22|James Spiro

In a climate where companies are cutting costs, one thing is worth holding on to: your patents.

Israeli companies and entrepreneurs should prepare for change in the European patent system

03.03.22|Guillaume Stern

In a few months, the United Patent Court and the European Patent System will start operating differently, having significant implications for those seeking to protect their Intellectual Property

IP not as a burden, but rather as a crucial business tool

08.11.21|Saleit Shahar

"Early-stage startups have limited financial and human resources to invest in IP. Together with the inherent problems in evaluating IP assets, startups do not always prioritize IP protection. However, as sometimes realized, the costs of lacking IP are higher," writes Saleit Shahar

Steve Krawczyk 20MinuteLeaders

"When you're an entrepreneur, you're always on display. You're always performing, and you're always questioning how the audience is receiving you"

Silicon Valley investor Steve Krawczyk talks to Michael Matias about the importance of grabbing opportunities, how patents play out in the pharma industry, and his role as an “emotional support angel”

מנת חיסון פייזר קורונה covid 19

How will Pfizer and Moderna protect their vaccine patent applications?

25.11.20|Adv. Ephraim Heiliczer

While regulatory exclusivity will effectively protect Covid vaccines for at least a decade in Europe and the U.S, they will be unprotected by regulatory exclusivity in Israel.

עסק קטן הקמת עסק סטארטאפ תוכנית עסקים קטנים 2

Reinhold Cohn and Calcalist to host 2021 startup competition

Contest is open to startups at seed and series A stages, top three winners will be awarded strategic, digital marketing, and storytelling services worth up to NIS 100,000

Five patents you should know about for Halloween 2020

29.10.20|Adv. Nathan Renov

Masks, decorations, and social distancing - here are the patents that are keeping us safe in a Halloween spooked with Covid-19

דניאל קליגלר פטנטים

The lawyer who forges Israeli tech companies’ prized weapons

23.10.20|Allon Sinai

Daniel Kligler, who specializes in patents, offers his unique insights on what makes Israelis dominate tech innovation

עו"ד אסא קלינג ראש מחלקת קניין רוחני במשרד עוה"ד נשיץ ברנדס אמיר ולשעבר ראש רשות הפטנטים

Israel Patent Office mulls U.S.-inspired provisional application

15.06.20|Hagar Ravet

Should the new model be adopted it would offer innovators a more accessible and less pricey route to patenting and could prove a source of revenue for the Israeli economy, according to intellectual property lawyer and former patent office director Asa Kling

אוניברסיטת תל אביב מעבדה בדיקות קורונה

As the pandemic continues to rage, patents should be protected without hampering innovation

08.06.20|Chavah Apfelbaum and Syvanne Aloni

Pioneers, who are navigating fragmented intellectual property laws across global markets, must be astute if they are to benefit from the significant commercial and geopolitical value of Covid-19-related ideas and products

מטה טבע פתח תקווה

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023

חברת ה תרופות טבע Teva

Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement

03.01.19|Lilach Baumer

In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug

מטה טבע פתח תקווה

Teva Reaches Confidential Patent Settlement with Neos

The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026

מטה טבע פתח תקווה

Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court

05.12.18|Lilach Baumer

Teva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018

Israelis Registered Fewer Patents, Scientific Discoveries in 2017

27.08.18|Meir Orbach

According to a new report by Israel's Central Bureau of Statistics, the number of newly registered patents in 2017 was down 5% compared with the year before. Registered scientific discoveries were down 19%

פרופסור זליג אשחר

Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court

28.05.18|Zohar Shahar Levy

Israeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights

פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy

Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights

פרופסור זליג אשחר

Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall

26.12.17|Zohar Shahar Levy

In August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments

מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer

Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone

בוריס בריאן רץ 800 לפני אתיופים ריו דה ז'נרו

Startup Contests Are Not for Everyone

22.10.17|Zachi Zach

If not carefully selected, a startup contest could hold more risk than value